First-line options for advanced HER2-mutant non-small cell lung cancer (NSCLC) are evolving as HER2-selective tyrosine kinase inhibitors (TKI) begin to generate prospective trial data. This article reviews first-line zongertinib outcomes from the Beamion LUNG-1 Phase Ib expansion, alongside other HER2-targeted TKIs, and discusses potential implications for US practice.*
